DexCom Posts Strong Q1 2026 Results, Lifts Margin Guidance as CGM Adoption Accelerates Globally
DexCom Inc. (NASDAQ: DXCM) delivered a solid first-quarter performance for 2026, posting revenue of $1.192 billion — a 15% increase from the same period last year. The growth was fueled by an 11% rise in U.S. revenue and a standout 26% jump in international sales, signaling expanding global adoption of continuous glucose monitoring (CGM) technology.
Beyond the top line, the company showed meaningful margin improvement. GAAP operating income came in at $255.3 million, or 21.4% of revenue, representing an 850-basis-point expansion compared to Q1 2025. That kind of leverage is catching the attention of analysts, especially in a med-tech environment where cost discipline is increasingly prized.
Strategically, DexCom made notable progress during the quarter. The expanded rollout of the DexCom G7 15-day CGM system and new features for the Stelo platform underscore the company's push to broaden its user base beyond traditional insulin-dependent patients. Clinical data presented at ATTD 2026 showed that the G7 significantly improved A1C levels in people with type 2 diabetes not using insulin — a key demographic that could unlock substantial market growth.
“This is the quarter where DexCom proved it can scale without sacrificing margins,” said Sarah Mitchell, a healthcare analyst at Summit Research Partners. “The international story is particularly compelling — 26% growth suggests they’re finally gaining traction outside the U.S. in a meaningful way.”
Not everyone is entirely convinced. “Look, the numbers are good, but the stock has been a rollercoaster,” said Mark Delaney, a retail investor and former medical device sales rep. “They keep talking about T2D non-insulin users, but adoption there is still slow. I want to see real patient uptake, not just conference abstracts.”
Looking ahead, DexCom raised its full-year 2026 guidance for non-GAAP operating margin to a range of 23% to 23.5%, and adjusted EBITDA margin to 31% to 31.5%. The company reaffirmed its annual revenue forecast of $5.16 billion to $5.25 billion, implying 11% to 13% growth. With $2.42 billion in cash and marketable securities as of March 31, the balance sheet remains a fortress.
DexCom continues to manufacture and market a range of CGM systems, including the G6, G7, Stelo, and the DexCom ONE platform, positioning itself as a leader in real-time glucose monitoring. As the company pushes deeper into Type 2 diabetes management and global markets, the next few quarters will be critical in determining whether this growth trajectory is sustainable.